• Vitamin C and NAC Mitigate Cochlear Cell Senescence via ROS/

  2026-07-28

  This study elucidates how vitamin C and N-acetylcysteine (NAC) ameliorate D-galactose-induced senescence in cochlear hair cells by inhibiting the ROS/NF-κB pathway. The findings offer mechanistic insight into oxidative stress pathway modulation relevant for age-related hearing loss research and highlight the translational utility of antioxidant interventions.

• Ceruletide in Pancreatic Function Research: Protocols & Insi

  2026-07-28

  Ceruletide (caerulein), a synthetic CCK analog, powers reproducible modeling of pancreatic fibrosis and digestive physiology. This guide delivers actionable workflows, literature-driven optimizations, and practical troubleshooting tips—helping researchers harness Ceruletide’s full potential in translational and preclinical studies.

• Moxifloxacin in Research: Protocols, Toxicity, and Metabolic

  2026-07-27

  Moxifloxacin, a broad-spectrum fluoroquinolone antibiotic, powers advanced research on DNA gyrase inhibition, cytotoxicity, and metabolic modulation. This article delivers stepwise experimental workflows, troubleshooting insights, and comparative innovation based on recent mechanistic studies—unlocking new frontiers in antibiotic toxicity and cellular response research.

• Protease and Phosphatase Inhibitor Cocktail (EDTA Free, 100X

  2026-07-27

  The Protease and Phosphatase Inhibitor Cocktail (EDTA Free, 100X in ddH2O) is a broad-spectrum reagent used to preserve protein integrity during extraction. This article details its molecular rationale, mechanism, and workflow integration, highlighting its suitability for preserving post-translational modifications in complex biological samples. Key evidence from recent sepsis research and best-practice protocols are included for reliable experimental design.

• Salmonella Haem Biosynthesis Inhibits Macrophage Phagocytosi

  2026-07-26

  This study reveals a mechanism by which Salmonella Typhimurium methylates a key enzyme in haem biosynthesis, increasing haem production to inhibit macrophage phagocytosis and enhance bacterial virulence in mice. The findings clarify how bacterial regulation of haem synthesis contributes to immune evasion, offering new perspectives for pathogen–host interaction research.

• Deferasirox: Oral Iron Chelator for Cancer Research Workflow

  2026-07-25

  Deferasirox, a clinically validated oral iron chelator, uniquely bridges iron overload therapy and advanced cancer research by modulating iron metabolism and ferroptosis resistance. This article delivers actionable protocols, troubleshooting strategies, and translational insights for leveraging Deferasirox in experimental models targeting tumor growth and iron homeostasis.

• In Vitro Synergy of TMP-Sulfonamide Combinations Against Equ

  2026-07-24

  This study systematically evaluated the in vitro activity of trimethoprim (TMP) and various sulfonamides against Salmonella strains isolated from horses, identifying sulfachlorpyridazine, sulfamethoxazole, and sulfadiazine as the most potent when combined with TMP. The findings guide rational antibiotic selection and dosing in veterinary medicine under conditions of emerging antimicrobial resistance.

• TMEM16F Lipid Scrambling: A Key Regulator of Ferroptosis and

  2026-07-24

  Yang et al. identify TMEM16F-mediated lipid scrambling as an essential regulator suppressing ferroptosis at the plasma membrane. Their findings reveal that disrupting this process not only sensitizes tumor cells to ferroptotic death, but also enhances tumor immune rejection, providing mechanistic insights with therapeutic implications.

• Trelagliptin Succinate: Applied Workflows for Diabetes Resea

  2026-07-23

  Trelagliptin succinate (SYR-472 succinate) stands out as a long-acting, selective DPP-4 inhibitor uniquely enabling once-weekly dosing and robust incretin modulation in preclinical and translational diabetes workflows. This guide distills validated protocols, troubleshooting strategies, and novel HPLC insights to maximize reproducibility and data quality in metabolic and comorbidity research.

• Octyl-α-ketoglutarate: Precision Tool for Prolyl Hydroxylase

  2026-07-23

  Octyl-α-ketoglutarate empowers researchers to dissect the hypoxia signaling pathway and restore prolyl hydroxylase activity in metabolically compromised cells. Its superior cell permeability and stability enable robust modeling of TCA cycle dysfunction and HIF-1α regulation for advanced cancer metabolism studies.

• Exogenous NADH Potentiates Antibiotic Efficacy in E. tarda M

  2026-07-22

  This study demonstrates that exogenous NADH reprograms the metabolism of multidrug-resistant Edwardsiella tarda, enhancing the bactericidal effect of aminoglycoside antibiotics such as neomycin. The findings suggest a promising metabolic modulation strategy to combat antibiotic resistance in both aquaculture and clinical settings.

• Cell Tumbling in 3D Hydrogels Drives Stem Cell Differentiati

  2026-07-22

  The referenced study uncovers a novel, rapid whole-cell movement—cell tumbling—in 3D hydrogels, showing it enhances stem cell differentiation by nuclear mechanotransduction. This mechanistic insight reshapes understanding of how physical cell behaviors in engineered niches regulate lineage commitment, with broad implications for tissue engineering and regenerative medicine.

• Ertugliflozin (PF-04971729): Selectivity, Mechanistic Insigh

  2026-07-21

  Explore the advanced selectivity and multifaceted mechanisms of Ertugliflozin (PF-04971729) in diabetes mellitus research. This article uniquely bridges molecular pharmacology with translational assay strategy, providing new perspectives beyond existing coverage.

• Tetracycline Hydrochloride: Mechanism and Antimicrobial Benc

  2026-07-21

  Tetracycline Hydrochloride, a bacteriostatic antibiotic, inhibits bacterial protein synthesis via 16S rRNA binding. It demonstrates proven efficacy against Staphylococcus aureus and Propionibacterium acnes, with well-characterized solubility and storage parameters.

• Nuclear Export Inhibition for TNBC: Insights from KPT-330 St

  2026-07-20

  This study systematically identified synergistic drug combinations for triple-negative breast cancer (TNBC) using high-throughput screening, highlighting KPT-330 (Selinexor) as a potent XPO1 inhibitor. Combined with a PI3K/mTOR inhibitor, KPT-330 significantly reduced tumor burden in preclinical TNBC models, supporting CRM1/XPO1 inhibition as a promising therapeutic avenue.

454 records 10/31 page Previous Next First page 上5页 678910 下5页 Last page